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PhospholipidsCardiolipin (CL), a unique mitochondrial phospholipid, plays a key role in several processes of mitochondrial
bioenergetics as well as in mitochondrial membrane stability and dynamics. The present study was designed
to determine the effect of MitoQ, a mitochondrial-targeted antioxidant, on the content of liver mitochondrial
membrane phospholipids, in particular CL, and its fatty acid composition in obesogenic diet-fed rats.
To do this, twenty-four 6 week old male Sprague Dawley rats were randomized into three groups of 8 animals
and fed for 8 weeks with either a control diet, a high fat diet (HF), or a HF diet with MitoQ (HF + MitoQ).
Phospholipid classes and fatty acid composition were assayed by chromatographic methods in liver and liver
mitochondria. Mitochondrial bioenergetic function was also evaluated. While MitoQ had no or slight effects on
total liver fatty acid composition and phospholipid classes and their fatty acid composition, it had major effects
on liver mitochondrial phospholipids and mitochondrial function. Indeed, MitoQ both increased CL synthase
gene expression and CL content of liver mitochondria and increased 18:2n-6 (linoleic acid) content ofmitochon-
drial phospholipids by comparison to the HF diet. Moreover, mitochondrial CL content was positively correlated
to mitochondrial membrane ﬂuidity, membrane potential and respiration, as well as to ATP synthase activity,
while it was negatively correlated to mitochondrial ROS production.
These ﬁndings suggest that MitoQ may decrease pathogenic alterations to CL content and proﬁles, thereby
preserving mitochondrial function and attenuating the development of some of the features of metabolic
syndrome in obesogenic diet-fed rats.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Metabolic syndrome comprises pathological conditions that include
visceral adiposity, insulin resistance (IR) and hepatic steatosis which
favor the development of type 2 diabetes and cardiovascular diseases
[1]. The liver plays amajor role in substratemetabolism and is a primary
target of insulin action, so it is at the crossroads of metabolism
and disease. Liver mitochondria are central to energy metabolism,
converting the energy stored in nutrients into ATP through the action
of oxidative phosphorylation. Mitochondria are also a major source of
cellular reactive oxygen species (ROS), which arise as byproducts of
the mitochondrial respiratory chain complexes. It is generally accepted
that the development of metabolic syndrome is accompanied withtpellier, France.
dray).mitochondrial dysfunction and increased mitochondrial ROS produc-
tion [2].
Phospholipids play multiple roles in cellular and organelle mem-
branes including establishing a permeability barrier, providing the
matrix for the assembly and function of awide variety of catalyzed reac-
tions, acting as donors in the synthesis of macromolecules and actively
inﬂuencing the functional properties of membrane-associated process-
es [3]. Prominent among mitochondrial phospholipids is cardiolipin
(CL) which is predominantly localized in the mitochondrial inner
membrane, at the heart of mitochondrial metabolism. Cardiolipin
is known to affect mitochondrial bioenergetics and contributes to mito-
chondrial membrane stability and dynamics [4]. In fact, signiﬁcant
changes in CL content/proﬁlemay altermembraneﬂuidity, organization
and functioning of the mitochondrial respiratory chain complexes and
their interactions, and may be associated with increased mitochondrial
production of ROS [5]. Therefore, alterations to CL content or its fatty
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tion in health and disease [6,7].
MitoQ is a mitochondrial-targeted antioxidant that is directed to the
matrix surface of the mitochondrial inner membrane where it is partic-
ularly effective against lipid peroxidation [8,9]. The effects of MitoQ on
the phospholipid content and the fatty acid composition of the mito-
chondrial membranes are unknown. Here, we assessed the hypothesis
that a redox-dependent modulation of CL content or fatty acid metabo-
lism could contribute to the development of metabolic syndrome [10]
and thatMitoQmight slow down this process [11]. To do this, we deter-
mined the effect of MitoQ on the phospholipid content and their fatty
acid composition of liver membranes and mitochondrial membranes
from obesogenic diet-fed rats, with a particular focus on CL content. In
addition, we also investigated how the modulation of mitochondrial
CL content and fatty acid composition impacted the function of liver
mitochondria.
2. Materials and methods
2.1. Animals and diets
Twenty four 6 week old male Sprague Dawley rats (Charles River,
L'Arbresle, France) were housed, 2 per cage, under conditions of
constant temperature (20–22 °C), humidity (45–50%) and a standard
dark cycle (20.00–08.00 h). The rats were randomized into three
groups of 8 animals each and fed for 8 weeks one of the following
semi-puriﬁed diets: 1) control diet with 4% lipid as soybean oil,
2) high fat diet (HF), and 3) HF diet with MitoQ (HF + MitoQ). The
macronutrient composition of these three diets is given in the Supple-
mentary Table 1. The HF diet contains 35% lipids (4% soybean
oil + 31% lard). The lipid fraction of the control diet was composed of
14% saturated fatty acids (SFA), 26% monounsaturated fatty acids
(MUFA) and 60% polyunsaturated fatty acids (PUFA), and that of the
HF diet was composed of 40% SFA, 42% MUFA and 18% PUFA (Supple-
mentary Table 2). MitoQ was used at the dose 0.86 g/kg diet in the
form of methanesulfonate β-cyclodextrin complex which corresponds
to 375 μmol MitoQ/kg diet. Rats were given free access to tap water
and food. Rat body weight and food consumption were determined
weekly. Our institution guidelines for the care and use of laboratory
animalswere observed and all experimental procedureswere approved
by the local ethical committee in Montpellier, France (Reference CEEA-
LR-12002).MitoQwas provided by Prof. R.A.J. Smith from theUniversity
of Otago in New Zealand.
2.2. Oral glucose tolerance test
The oral glucose tolerance test (OGTT) was completed four to ﬁve
days before rat sacriﬁce and performed as previously described [11].
Brieﬂy, 16-hours fasting rats received by gavage 2 g glucose/kg body
weight. Blood was sampled through the tail vein of conscious rats
immediately prior to the gavage, and 20, 40, 60, 90, 120 and 180 min
afterward and blood glucose was measured using glucose strips and a
commercial glucometer (AccuChek Active, Roche Diagnostics, USA).
The area under the curve (AUC) was calculated by the trapeziummeth-
od. The AUC values are expressed as mg glucose·dl−1/min.
2.3. Sampling and routine biochemical analysis
Four to ﬁve days after the OGTT, 16 hours-fasted rats were anesthe-
tized with pentobarbital (40 mg/kg b.w.) (Ceva Santé Animale,
Libourne, Fr) and blood was drawn from the abdominal artery with a
heparinized syringe and distributed into dry and heparinized tubes.
Blood tubes were centrifuged at 1000 g for 10 min at 4 °C, plasma or
serum was collected and stored at−80 °C until analysis. Liver was re-
moved, rinsed with 0.9% NaCl and cut into 2 parts: one part was frozenin nitrogen and kept at−80 °C until analysis, and one part was used for
the immediate isolation of fresh mitochondria.
Plasma glucose, serum total cholesterol, triglycerides and free fatty
acid levels were measured by enzymatic techniques (Konelab, Thermo
Electron Corp., Vantaa, Finland). Plasma insulin and leptin were quanti-
ﬁed with ELISA kits (Merck Millipore, Darmstadt, Allemagne). Insulin
resistance (IR) was evaluated by the homeostasis model of IR (HOMA-
IR) formula [11].
2.4. Liver mitochondrial isolation
Liver mitochondria were isolated from fresh liver by the differential
centrifugation technique [12]. Brieﬂy, about 3 g of liver was homoge-
nized in 10 volumes of sucrose buffer (sucrose 0.25 M, Tris 10 mM,
EDTA 0.5 mM, pH 7.5) and centrifuged at 900 g for 10 min at +4 °C.
The supernatant was then centrifuged at 10,000 g for 10 min at
+4 °C. The pellet was suspended in 3 mL of sucrose buffer. One aliquot
of the mitochondrial suspension was used for mitochondrial function
measurement [11] and one aliquot was frozen at −80 °C for lipid
measurement. Protein content was determined according to Bradford
with bovine serum albumin as the standard [13].
2.5. Liver TAG, FFA and cholesterol analysis
Liver samples were homogenized in NaCl (9 g/L) and Triton X-100
(0.1%) and free fatty acids, triglycerides and total cholesterol levels
were quantiﬁed on the liver homogenate by enzymatic methods using
Wako-NEFA-C kit (Oxoid, Dardilly, France) and Cholesterol RTU kit
and triglycerides PAP kit (Biomérieux, Lyon, France).
2.6. Liver phospholipid separation and analysis
Liver samples and liver mitochondrial suspensions were extracted
by a mixture of chloroform/methanol 2:1 (v/v) according to Folch
et al. [14] in the presence of 50 mg/L of butylated hydroxytoluene.
Phosphorus was quantiﬁed on Folch extracts of both liver samples and
mitochondrial suspensions in order to determine total phospholipid
quantity as previously described [15].
The application of Folch extracts of both liver samples and
mitochondrial suspensions on silica gel 60 HPTLC plates (250 μm,
20 ∗ 10 cm,Merck, Germany) pretreatedwith 2.3%w/v boric acid in eth-
anol (100%), was automatically performed on a 4mmbandwidth using
a CAMAG ATS4 apparatus (Muttenz, Switzerland). The development
was performed with methanol/acetic acid/pentane/chloroform (15/
10/30/45, by volume), which allowed the separation of phospholipids
and neutral lipids on a 60 mm total migration distance. The scanning
of the plates was carried out using a CAMAG TLC scanner 3 (Muttenz,
Switzerland), operating in the reﬂectance mode. The plates were
scanned at 715 nm after dipping in a solution of Blue Spray (Sigma,
France) (1/2/3 v/v/v, Blue Spray/H2SO4 4.2 M/acetone) and heating for
3 mn at 55 °C. The different classes of phospholipids (SM, LPC, PC, PI,
PS, PE, PG, PA, CL) were identiﬁed by comparing their retention factor
(Rf) to authentic standards and quantiﬁed using calibration curves of
the same standards.
2.7. Analysis of fatty acids in liver, liver phospholipids and liver
mitochondrial phospholipids
To determine the fatty acid composition of the liver lipids, the
Folch extracts of liver were used. To determine the fatty acid compo-
sition of liver phospholipids and liver mitochondrial phospholipids,
the phospholipid fractions were separated from other neutral lipids,
in the Folch extracts of both liver samples andmitochondrial suspen-
sions, on TLC plates with hexane/diethyl ether/glacial acetic acid
mixture (70:30:1, v/v/v). Plates were dried and then sprayed with
dichloroﬂuorescein. Bands corresponding to phospholipids were
Table 1
Rat characteristics and metabolic plasma and liver analyses.
Control diet HF diet HF + MitoQ diet
Rat characteristics
Weight gain (g/rat/d) 6.45 ± 0.37 7.33 ± 0.64* 6.71 ± 0.71
Final body weight (g) 581 ± 32 632 ± 36* 597 ± 47
Dietary intake (g/rat/d) 26.9 ± 1.0 20.6 ± 0.9* 18.6 ± 0.9*§
Energy intake (kcal/rat/d) 97 ± 4 111 ± 5* 100 ± 5§
Blood analyses
Glucose (mg/dL) 162 ± 14 156 ± 8 162 ± 14
OGTT (AUC mg·dl−1/min) 127 ± 11 145 ± 20* 136 ± 13
Insulin (μg/L) 6.18 ± 1.94 6.44 ± 1.56 3.85 ± 1.89*§
HOMA-IR 61.0 ± 19.0 61.4 ± 14.6 35.5 ± 18.6*§
Leptin (μg/L) 4.25 ± 1.33 8.86 ± 3.16* 6.48 ± 3.14
FFA (mmol/L) 0.595 ± 0.104 0.444 ± 0.083* 0.411 ± 0.060*
Cholesterol (mmol/L) 2.19 ± 0.51 1.55 ± 0.12* 1.76 ± 0.21
Triglycerides (mmol/L) 1.44 ± 0.41 1.04 ± 0.31 0.94 ± 0.25*
Liver analyses
Liver weight (g) 14.0 ± 1.0 17.1 ± 2.0* 15.4 ± 2.3
(Liver / body weight) × 100 2.41 ± 0.11 2.69 ± 0.21* 2.57 ± 0.25
FFA (μmol/g ww) 25.4 ± 5.4 51.4 ± 9.8* 51.3 ± 8.7*
Cholesterol (μmol/g ww) 10.8 ± 1.7 16.2 ± 1.7* 17.4 ± 1.9*
TAG (μmol/g ww) 52 ± 15 142 ± 28* 147 ± 21*
Phospholipids (μmol/g ww) 35.2 ± 2.3 31.7 ± 3.1* 32.8 ± 2.6
Results aremean± SD; n= 8. Unpaired t-test. Signiﬁcance was set at p b 0.05.* vs control
and § vs HF.
HOMA-IR was calculated as follows: (fasting plasma glucose mM× fasting plasma insulin
mU/L) / 22.5; OGTT: oral glucose tolerance test; AUC: area under curve; ALAT: alanine
amino transaminase; ASAT: aspartate amino transaminase, ww: wet weight.
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into a glass tube.
The fatty acids of total liver lipids, liver phospholipids and liver
mitochondrial phospholipids were trans-esteriﬁed with an alkali mix-
ture of KOH–methanol for 10 min at room temperature. The total fatty
acid methyl ester pattern including the cis and trans PUFA was then an-
alyzed by gas chromatography (Agilent Technologies, Milan, Italy)
equipped with a DB-23 column and a ﬂame ionization detector. GC
conditions have been described elsewhere [16]. Chromatograms were
recorded, and peaks were integrated and identiﬁed by comparison
with commercially available references. The FA composition of liver
total lipids, liver phospholipids and mitochondrial phospholipids were
compared in terms of the percentage content of various fatty acids.
2.8. Tissue desaturase indices and unsaturation index
Because it is not possible to directly measure the activity of the
enzymes that catalyze the desaturation and elongation reactions in
the fatty acid metabolic pathways, results in animals have supported
the use of surrogate measures of desaturase activity such as use of
desaturase indices [17]. These indices are based on the ratio of product
to precursor of individual fatty acids. The desaturase indiceswere calcu-
lated as follows: Δ9, [16:1 n-7/16:0]; Δ6, [18:3 n-6/18:2 n-6]; and Δ5,
[20:4 (n-6)/20:3 (n-6)]. The unsaturation index (UI) was calculated
from the relative percentage of each type ofmono- and polyunsaturated
fatty acid (see Tables 2, 4 and 6) multiplied for the number of double
bonds present in the molecule [18].
2.9. Mitochondrial characteristics and enzyme activities
The liver mitochondrial membrane ﬂuidity, membrane potential
and ROS production were assessed as previously described [12,19].
Mitochondrial respirationwas determined bymeasuringmitochondrial
oxygen consumption in a high resolution Oxygraph (Oroboros
Oxygraph2k, Austria) [12]. Citrate synthase activity and the activities of
the mitochondrial respiratory complexes (complex I, complex II + III,
complex IV and ATP synthase) in liver mitochondria were determined
spectrophotometrically as described previously [18].
2.10. Reverse transcription q-PCR analyses
Reverse transcription quantitative real-time polymerase chain reac-
tion (RT-qPCR) was used to measure target genes mRNA expression in
liver. These genes include CDP-diacylglycerol synthase 1 and 2 (CDS1,
CDS2), phosphatidylglycerophosphate synthase 1 (PGS1), cardiolipin
synthase (CLS), lysocardiolipin acyltransferase 1 (LCLAT1), and tafazzin
(TAZ). Ribosomal RNA (18S) was used as control. Total RNA was
extracted with Trizol reagent (Invitrogen Life Technologies, Cergy
Pontoise, France). Reverse transcription reaction was performed with
2 μg total RNA. cDNA was synthesized with the use of SuperScript II
Reverse Transcriptase for ﬁrst strand cDNA synthesis (Invitrogen Life
Technologies, Cergy Pontoise, France) and oligo (dT) primers. The
mRNA expressions of target genes were determined by RT-qPCR. RT-
qPCR analysis was performed using IQ™ SYBR Green Supermix (Biorad,
Hercules, CA, USA) with a MiniOpticon detection system (Biorad,
Hercules, CA, USA). Results were normalized to the gene encoding 18S
ribosomal RNA. The primer sequences used for real-time RT-PCR are
given on the Supplementary Table 3.
2.11. Statistical analysis
Data are expressed asmeans± SD. Unpaired t-tests were performed
to detect statistical signiﬁcance between control diet and the HF diet or
HF + MitoQ diet and between the HF diet and the HF + MitoQ diet.
Correlations were performed with the Spearman method. The limit ofstatistical signiﬁcance was set at p b 0.05. Statistical analyses were
performed using the StatView program (SAS Institute, Cary, NC, USA).
3. Results
3.1. Characterization of the rat metabolic syndrome model
Weight gain at the end of the experiment was increased by feeding
the HF diet compared to the control diet. Moreover, even though the
weight of food consumed by rats on the HF diet was lower than for
the control diet, the energy intake was increased (Table 1). With the
HF + MitoQ diet, the weight gain was the same as for the control diet,
while both dietary and energy intakes with HF + MitoQ diet were
lower than with the HF diet.
While plasma glucose was not modiﬁed in the three groups, plasma
insulin level and HOMA-IR index were decreased signiﬁcantly with the
HF+MitoQ diet compared to the control and HF diets (Table 1). More-
over, the AUC after OGTT and plasma leptin level were increased with
the HF diet compared to the control diet, while their increases were
largely attenuated with the HF +MitoQ diet.
Plasma free fatty acid and total cholesterol levels were decreased
with the HF diet and the plasma levels of free fatty acids and triglycer-
ideswere decreased with the HF+MitoQ diet, compared to the control
diet (Table 1). In addition, as expected, liver weight and liver free fatty
acids, triglycerides and total cholesterol levels were increased with
both the HF and the HF + MitoQ diets compared to the control diet,
reﬂecting overt liver steatosis (Table 1).
3.2. Liver fatty acid composition and desaturase indices
The main saturated fatty acids in liver were represented by palmitic
acid (16:0) and stearic acid (18:0). If the palmitic acid level remained
unchanged, the stearic acid level was signiﬁcantly decreased with HF
and HF + MitoQ diets compared to the control diet. So, the liver total
SFA level was decreased with HF and HF + MitoQ diets compared to
the control diet (Table 2). The liver oleic acid (18:1 n-9) levelwas signif-
icantly increased, while those of palmitoleic (16:1 n-7) and vaccenic
acids (18:1 n-7) were decreased with HF and HF + MitoQ diets
Table 2
Fatty acid composition of liver lipid extract.
Control diet HF diet HF ± MitoQ diet
Total SFA 31.1 ± 2.1 28.1 ± 0.8* 28.1 ± 1.0*
16:0 23.7 ± 1.5 23.2 ± 0.7 23.1 ± 0.9
18:0 7.40 ± 1.54 4.87 ± 0.57* 5.00 ± 0.72*
Total MUFA 30.9 ± 3.2 39.2 ± 2.8* 38.7 ± 1.7*
16:1 n-7 6.67 ± 1.70 1.39 ± 0.28* 1.15 ± 0.31*
18:1 n-9 19.4 ± 1.6 34.6 ± 2.6* 34.5 ± 1.6*
18:1 n-7 4.32 ± 1.04 2.77 ± 0.22* 2.63 ± 0.15*
Total PUFA 38.0 ± 3.8 32.7 ± 3.3* 33.1 ± 2.1*
18:2 n-6 16.3 ± 3.0 21.7 ± 1.7* 22.5 ± 1.2*
18:3 n-6 0.353 ± 0.078 0.277 ± 0.035* 0.285 ± 0.046
18:3 n-3 1.06 ± 0.68 1.26 ± 0.29 1.29 ± 0.27
20:3 n-6 0.425 ± 0.137 0.424 ± 0.070 0.440 ± 0.061
20:4 n-6 14.6 ± 2.0 6.19 ± 1.36* 5.80 ± 0.96*
20:5 n-3 0.207 ± 0.041 0.214 ± 0.051 0.220 ± 0.035
22:5 n-3 0.399 ± 0.098 0.567 ± 0.063* 0.617 ± 0.159 *
22:6 n-3 4.12 ± 0.59 1.83 ± 0.28* 1.75 ± 0.24*
Total (n-6) 32.2 ± 3.3 28.8 ± 2.9* 29.2 ± 1.8*
Total (n-3) 5.78 ± 0.95 3.87 ± 0.49* 3.87 ± 0.37*
n-6/n-3 5.66 ± 0.85 7.47 ± 0.48* 7.58 ± 0.49*
Total trans 0.493 ± 0.268 0.267 ± 0.106* 0.254 ± 0.110*
18:1 (n-9)t 0.054 ± 0.037 0.038 ± 0.009 0.038 ± 0.010
18:2 (n-6)t 0.238 ± 0.067 0.122 ± 0.026* 0.104 ± 0.040*
20:4 (n-6)t 0.201 ± 0.304 0.108 ± 0.126 0.112 ± 0.126
SFA/MUFA£ 1.02 ± 0.13 0.718 ± 0.041* 0.728 ± 0.037*
PUFA/SFA# 1.23 ± 0.18 1.17 ± 0.15 * 1.18 ± 0.11*
n-3/PUFA& 0.152 ± 0.019 0.118 ± 0.007* 0.117 ± 0.006*
UI$ 136 ± 10 94 ± 10* 93 ± 7*
Δ9-desaturase
16:1 n-7/16:0 0.280 ± 0.063 0.060 ± 0.012* 0.050 ± 0.014*
Δ6-desaturase
18:3 n-6/18:2 n-6 0.023 ± 0.008 0.013 ± 0.002* 0.013 ± 0.002*
Δ5-desaturase
20:4 n-6/20:3 n-6 37.7 ± 12.4 14.8 ± 3.2* 13.4 ± 3.1*
Results are mean± SD; n= 8. Unpaired t-test. Signiﬁcance was set at p b 0.05.* vs control
and § vs HF.
Major fatty acids are represented and results are expressed as percentage of fatty acids in
total PL.
SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated
fatty acids.
£ SFA/MUFA: SFA = %C16:0 + %C18:0 and MUFA = %C16:1 + %C18:1.
# PUFA/SFA: SFA = %C16:0 + %C18:0 and PUFA = %all PUFA.
& n-3/PUFA: total (n-3) / all PUFA.
$ UI: unsaturation index = (%monoenoic*1) + (%dienoic*2) + (%trienoic*3) +
(%tetraenoic*4) + (%pentaenoic*5) + (%hexaenoic*6).
Table 3
Abundance of phospholipid classes in liver lipid extract.
Control diet HF diet HF + MitoQ diet
SM (% nmol) 4.59 ± 1.01 4.25 ± 0.52 4.68 ± 0.65
PC (% nmol) 54.5 ± 1.9 51.7 ± 1.8* 51.1 ± 1.5*
PI (% nmol) 7.25 ± 0.64 7.91 ± 1.08 7.74 ± 1.23
PS (% nmol) 2.72 ± 0.58 2.54 ± 0.91 2.97 ± 0.72
PE (% nmol) 25.8 ± 0.9 27.5 ± 1.3* 27.5 ± 1.3*
CL (% nmol) 5.16 ± 0.68 6.08 ± 0.68* 6.10 ± 0.74*
PC/PE 2.12 ± 0.11 1.89 ± 0.15* 1.86 ± 0.12*
Results aremean± SD; n= 8. Unpaired t-test. Signiﬁcance was set at p b 0.05.* vs control
and § vs HF.
Results are expressed as percentage of nmol of phosphorus in PL.
SM: sphingomyelin, PC: phosphatidylcholine, PI: phosphatidylinositol, PS: phospha-
tidylserine, PE: phosphatidylethanolamine, CL: cardiolipin.
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increased (+25%) with HF and HF+MitoQ diets compared to the con-
trol diet. The levels of the two major PUFA: linoleic acid (18:2 n-6) and
arachidonic acid (20:4 n-6) were respectively increased and decreased
with HF and HF + MitoQ diets compared to the control diet. However,
the level of total n-6 PUFA was decreased with HF and HF + MitoQ
diets compared to the control diet (−15%). Moreover, the level
of total n-3 PUFA was dramatically decreased with the HF + MitoQ
diet compared to the control diet (−33%), with the change in
docosahexaenoic acid (22:6, n-3) being particularly notable (−55%).
Interestingly, the level of trans fatty acids was decreased (−45%) with
HF and HF + MitoQ diets, in comparison to the control diet, mainly
because of a marked decrease in trans linoleic acid (trans 18:2 n-6)
level (−50%). Overall, the MitoQ intake did not affect liver fatty acid
content in HF + MitoQ diet-fed rats, compared to HF diet-fed rats.
Regarding the fatty acid desaturase activities (Δ9, Δ6 and Δ5) from
the liver total lipid content, the respective indices of these desaturases
[16:1n-7/16:0], [18:3n-6/18:2n-6] and [20:4n-6/20:3n-6] were
dramatically decreased with HF and HF + MitoQ diets compared to
the control diet. Consequently, the unsaturation index (UI) was de-
creased with HF and HF + MitoQ diets compared to the control diet.
This is in line with the marked decrease in desaturase activities and intotal polyunsaturated fatty acids with HF and HF + MitoQ diets when
compared to the control diet.3.3. Liver phospholipid classes
The assessment of the liver content of two major phospholipid
classes, phosphatidylcholine (PC) and phosphatidylethanolamine (PE),
showed that PC decreased while PE increased with HF and HF + MitoQ
diets compared to the control diet, thereby causing the PC/PE ratio
to decrease (Table 3). The contents of phosphatidylinositol (PI),
phosphatidylserine (PS) and sphingomyelin (SM), remained un-
changed under all conditions, while that of CL was increased to the
same extent with both HF and HF + MitoQ diets compared to the
control diet.3.4. Fatty acid composition of liver phospholipids and desaturase indices
The analysis of fatty acid composition of liver phospholipids showed
that the palmitic acid (16:0) level was decreased while the stearic acid
(18:0) level was increased with HF and HF + MitoQ diets. Overall, the
level of total SFA was slightly but signiﬁcantly increased with HF and
HF + MitoQ diets (+10%) compared to the control diet (Table 4).
The level of oleic acid (18:1 n-9) in the liver phospholipids was
increased, while palmitoleic acid (16:1 n-7) and vaccenic acid
(18:1 n-7) levels were decreasedwith HF andHF+MitoQ diets com-
pared to the control diet. Moreover, the levels of palmitoleic and
vaccenic acids were further decreased by the HF + MitoQ diet com-
pared to the HF diet. Finally, the level of total MUFAwas only decreased
with the HF +MitoQ diet compared to both control and HF diets.
The level of linoleic acid (18:2 n-6) in the liver phospholipids was
increased, while the level of γ-linolenic acid (18:3 n-6) was decreased
with HF and HF + MitoQ diets compared to the control diet, whereas
the major PUFA, 20:4 n-6, remained unchanged. So, the levels of total
n-6 PUFA remained unchanged in the three experimental groups.
Regarding then-3 PUFAs,when theHF andHF+MitoQdietswere com-
pared to the control diet the levels of eicosapentaenoic acid (20:5 n-3)
and docosahexaenoic acid (22:6 n-3) were decreased, while that of
22:5 n-3 was increased, and the level of α-linolenic acid (18:3 n-3)
remained unchanged. Finally, the level of n-3 PUFA was decreased
with the HF and HF + MitoQ diets compared to the control diet, while
the combined level of n-6 PUFA plus n-3 PUFA remained unchanged
in the three experimental groups.
The level of trans linoleic acid (trans 18:2 n-6) decreasedwith theHF
and HF+MitoQ diets, while that of trans oleic acid (trans 18:1n-9) was
only decreased with the HF+MitoQ diet compared to the control diet,
and that of trans arachidonic acid (trans 20:4n-6) remained unchanged.
Finally, the overall level of trans fatty acids remained unchanged in the
three experimental groups.
Table 4
Fatty acid composition of liver phospholipid extract.
Control diet HF diet HF + MitoQ diet
Total SFA 38.7 ± 1.5 40.9 ± 1.1* 41.4 ± 0.7*
16:0 17.5 ± 1.0 16.1 ± 0.7* 15.7 ± 0.6*
18:0 21.3 ± 2.1 24.8 ± 1.5* 25.7 ± 0.8*
Total MUFA 8.79 ± 1.45 8.09 ± 1.51 6.87 ± 1.12*
16:1 n-7 1.25 ± 0.24 0.310 ± 0.063* 0.237 ± 0.052*§
18:1 n-9 3.85 ± 0.73 5.88 ± 1.46* 4.89 ± 1.06*
18:1 n-7 3.56 ± 0.77 1.75 ± 0.06* 1.63 ± 0.08*§
Total PUFA 52.4 ± 1.40 51.0 ± 1.22 51.7 ± 0.87
18:2 n-6 9.58 ± 1.64 11.1 ± 0.96* 11.5 ± 0.30*
18:3 n-6 0.129 ± 0.026 0.074 ± 0.018* 0.060 ± 0.017*
18:3 n-3 0.398 ± 0.498 0.253 ± 0.165 0.333 ± 0.247
20:3 n-6 0.859 ± 0.286 0.878 ± 0.182 0.861 ± 0.093
20:4 n-6 30.7 ± 1.1 29.8 ± 1.5 30.4 ± 1.0
20:5 n-3 0.115 ± 0.026 0.074 ± 0.018* 0.082 ± 0.024*
22:5 n-3 0.707 ± 0.106 0.958 ± 0.096 * 0.899 ± 0.172 *
22:6 n-3 9.38 ± 1.08 7.56 ± 0.42* 7.21 ± 0.37*
Total (n-6) 41.8 ± 1.53 42.2 ± 1.31 43.2 ± 0.89
Total (n-3) 10.6 ± 1.2 8.85 ± 0.52* 8.53 ± 0.48*
n-6/n-3 4.00 ± 0.56 4.79 ± 0.36* 5.08 ± 0.36*
Total trans 0.642 ± 0.314 0.419 ± 0.192 0.387 ± 0.181
18:1 (n-9)t 0.060 ± 0.014 0.057 ± 0.020 0.044 ± 0.013*
18:2 (n-6)t 0.265 ± 0.067 0.090 ± 0.027* 0.060 ± 0.027*§
20:4 (n-6)t 0.316 ± 0.294 0.271 ± 0.161 0.284 ± 0.165
SFA/MUFA£ 4.53 ± 0.88 5.24 ± 1.17 6.18 ± 1.03*
PUFA/SFA# 1.36 ± 0.08 1.25 ± 0.05 * 1.25 ± 0.03*
n-3/PUFA& 0.202 ± 0.022 0.173 ± 0.011* 0.165 ± 0.009*
UI$ 215 ± 5 203 ± 4* 203 ± 3*
Δ9-desaturase
16:1 n-7/16:0 0.071 ± 0.012 0.019 ± 0.004* 0.015 ± 0.003*§
Δ6-desaturase
18:3 n-6/18:2 n-6 0.014 ± 0.004 0.007 ± 0.002* 0.005 ± 0.001*
Δ5-desaturase
20:4 n-6/20:3 n-6 39.2 ± 12.0 35.4 ± 7.7 35.7 ± 3.8
Results are mean± SD; n= 8. Unpaired t-test. Signiﬁcance was set at p b 0.05.* vs control
and § vs HF.
Major fatty acids are represented and results are expressed as percentage of fatty acids in
total PL.
SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated
fatty acids.
£ SFA/MUFA: SFA = %C16:0 + %C18:0 and MUFA = %C16:1 + %C18:1.
# PUFA/SFA: SFA = %C16:0 + %C18:0 and PUFA = %all PUFA.
& n-3/PUFA: total (n-3) / all PUFA.
$ UI: unsaturation INDEX = (%monoenoic*1) + (%dienoic*2) + (%trienoic*3) +
(%tetraenoic*4) + (%pentaenoic*5) + (%hexaenoic*6).
Table 5
Abundance of phospholipid classes in liver mitochondrial lipid extract.
Control diet HF diet HF + MitoQ diet
Total PL (nmol/mg prot) 313 ± 85 304 ± 80 308 ± 84
SM (% nmol) 2.03 ± 1.55 1.87 ± 1.26 2.58 ± 1.87
PC (% nmol) 51.4 ± 1.7 48.5 ± 1.2* 47.0 ± 0.9*§
PI (% nmol) 3.91 ± 1.53 4.27 ± 0.99 5.23 ± 1.33
PS (% nmol) 1.60 ± 0.38 1.59 ± 0.35 1.63 ± 0.37
PE (% nmol) 32.3 ± 1.9 34.3 ± 2.4 33.3 ± 2.3
CL (% nmol) 8.81 ± 0.62 9.37 ± 0.38* 10.2 ± 0.87*§
PC/PE 1.60 ± 0.11 1.42 ± 0.13* 1.42 ± 0.11*
Results aremean± SD; n= 8. Unpaired t-test. Signiﬁcance was set at p b 0.05.* vs control
and § vs HF.
Results are expressed as percentage of nmol of phosphorus in PL.
SM: sphingomyelin, PC: phosphatidylcholine, PI: phosphatidylinositol, PS: phospha-
tidylserine, PE: phosphatidylethanolamine, CL: cardiolipin.
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the indices of Δ9 [16:1n-7/16:0], and Δ6 [18:3n-6/18:2n-6]
desaturase activity were dramatically decreased whereas the index
of Δ5-desaturase activity [20:4n-6/20:3n-6] was only non-signiﬁcantly
decreased with HF and HF + MitoQ diets compared to the control diet.
Moreover, the index of Δ9 desaturase activity [16:1n-7/16:0] was further
decreased with HF + MitoQ diet-fed rats compared to HF diet.
Unsaturation index (UI) was decreased with HF and HF + MitoQ diets
compared to control diet. This is also in line with the marked decrease
in desaturase activities and in total polyunsaturated fatty acids with HF
and HF +MitoQ diets compared to control diet.
3.5. Mitochondrial phospholipid classes
The total phospholipid content in the liver mitochondria was the
same for the three experimental diets (Table 5). The percent of PC
decreased with HF and HF + MitoQ fed rats compared to control fed
rats, whereas PE percent remained unchanged, thereby leading to a
signiﬁcant decrease in the PC/PE ratio. More interestingly, CL content
was signiﬁcantly increased with HF (+7%) and HF + MitoQ (+16%)
rats compared to control rats. In addition, CL content was signiﬁcantly
increased in HF +MitoQ (+9%) rats compared to HF rats. The content
of the other phospholipid classes PE, PI, PS and SM remained
unchanged.3.6. Fatty acid composition of liver mitochondrial phospholipids and
desaturase indices
The fatty acid analysis of liver mitochondrial phospholipids showed
that the palmitic acid (16:0) level was decreased and the stearic
acid (18:0) level was increased with HF and HF + MitoQ diets com-
pared to the control diet, so the total SFA content remained unchanged
among the groups (Table 6). In contrast, the levels of both palmitoleic
(16:1 n-7) and vaccenic acids (18:1 n-7) were decreased, but the level
of oleic acid (18:1 n-9) was increased with HF and HF + MitoQ diets
compared to the control diet. In addition, palmitoleic acid (16:1 n-7)
level was further decreased with HF + MitoQ diet compared to HF
diet. Overall, the content of total MUFA was decreased with the HF
and HF + MitoQ diets, compared to the control diet (Table 6).
The level of the PUFA linoleic acid (18:2 n-6) was signiﬁcantly
increased with HF + MitoQ diet compared to the control diet (+30%).
Moreover, its level was 11 % greater with the HF + MitoQ diet
than with the HF diet, which was nearly signiﬁcant (p = 0.0527). The
γ-linolenic acid (18:3 n-6) level was signiﬁcantly decreased with the
HF and HF + MitoQ diets compared to the control diet, whereas that
of the predominant PUFA arachidonic acid (20:4 n-6) remained
unchanged. The major n-3 PUFA, DHA (22:6 n-3), was signiﬁcantly de-
creased, while the docosapentaenoic acid (22:5 n-3) was signiﬁcantly
increased with the HF and HF + MitoQ diets compared to the control
diet. Finally, the level of n-6 PUFA levels was increased and that of n-3
PUFA was decreased and thus the (n-6)/(n-3) ratio was signiﬁcantly
increased with HF +MitoQ compared to the control diet (Table 6).
The total trans fatty acid contentwas decreasedwith theHF+MitoQ
diet compared to the control diet, mainly because of a decrease in the
trans linoleic acid (trans 18:2 n-6) content. The SFA/MUFA ratio was
increased with HF and HF + MitoQ diets, whereas PUFA/SFA ratio was
decreased only with the HF diet while the n-3/PUFA ratio decreased
only with the HF +MitoQ diet compared to the control diet (Table 6).
The fatty acid analysis of liver mitochondria phospholipids
has shown that the indices of Δ9 [16:1n-7/16:0], and Δ6 [18:3n-6/
18:2n-6] desaturase activity were dramatically decreased with HF and
HF + MitoQ diets compared to the control diet, whereas the index of
Δ5 desaturase activity [20:4n-6/20:3n-6] remained unchanged. More-
over, the index of Δ9 desaturase activity [16:1n-7/16:0] was further
decreased with HF + MitoQ diet-fed rats compared to the HF diet.
Unsaturation index (UI) decreased in HF diet-fed rats in comparison
to controls, but not in HF-MitoQ diet-fed rats (Table 6).3.7. Liver mRNA expression of genes involved in CL synthesis
and remodeling
The livermRNAexpression of two key enzymes in the CL remodeling
pathway, namely CDP-diacylglycerol synthase (CDS1) and CL synthase
(CLS), was increased with the HF and HF + MitoQ diets compared to
Table 6
Fatty acid composition of liver mitochondrial phospholipids.
Control diet HF diet HF + MitoQ diet
Total SFA 41.0 ± 1.64 42.7 ± 0.9 41.7 ± 1.8
16:0 18.3 ± 0.6 17.0 ± 0.9* 16.2 ± 0.6*
18:0 22.7 ± 2.1 25.7 ± 1.0* 25.5 ± 1.8*
Total MUFA 8.39 ± 0.82 6.37 ± 0.76* 5.96 ± 0.44*
16:1 n-7 1.28 ± 0.17 0.33 ± 0.05* 0.22 ± 0.04 *§
18:1 n-9 2.99 ± 0.28 4.00 ± 0.60* 3.87 ± 0.30*
18:1 n-7 3.98 ± 0.79 1.92 ± 0.18* 1.75 ± 0.16*
Total PUFA 50.6 ± 1.05 50.9 ± 1.16 52.3 ± 1.68
18:2 n-6 9.94 ± 1.53 11.5 ± 1.16 12.8 ± 0.81*
18:3 n-6 0.106 ± 0.044 0.047 ± 0.023* 0.054 ± 0.023*
18:3 n-3 1.021 ± 1.541 0.426 ± 0.198 0.314 ± 0.102
20:3 n-6 0.881 ± 0.304 0.892 ± 0.119 0.865 ± 0.184
20:4 n-6 27.4 ± 1.3 28.0 ± 0.5 28.6 ± 1.11
20:5 n-3 0.114 ± 0.037 0.099 ± 0.058 0.082 ± 0.015
22:5 n-3 0.761 ± 0.044 0.954 ± 0.047* 0.975 ± 0.199*
22:6 n-3 9.75 ± 1.21 8.56 ± 0.57* 8.36 ± 0.41*
Total (n-6) 38.9 ± 2.0 40.9 ± 1.5 42.6 ± 1.3*
Total (n-3) 11.6 ± 1.8 10.0 ± 0.5 9.73 ± 0.52*
n-6/n-3 3.43 ± 0.65 4.08 ± 0.33 4.39 ± 0.20*
Total trans 0.664 ± 0.192 0.550 ± 0.156 0.433 ± 0.119*
18:1 (n-9)t 0.053 ± 0.031 0.058 ± 0.026 0.048 ± 0.021
18:2 (n-6)t 0.258 ± 0.062 0.097 ± 0.042* 0.086 ± 0.036*
20:4 (n-6)t 0.330 ± 0.181 0.390 ± 0.165 0.289 ± 0.122
SFA/MUFA£ 2.79 ± 0.50 4.15 ± 0.11* 4.39 ± 0.22*
PUFA/SFA# 2.22 ± 0.22 1.96 ± 0.05* 2.05 ± 0.05
n-3/PUFA& 0.230 ± 0.036 0.197 ± 0.013 0.186 ± 0.007*
UI$ 207 ± 2 202 ± 3* 205 ± 7
Δ9-desaturase
16:1 n-7/16:0 0.070 ± 0.010 0.020 ± 0.004* 0.014 ± 0.003*§
Δ6-desaturase
18:3 n-6/18:2 n-6 0.011 ± 0.004 0.004 ± 0.002* 0.004 ± 0.002*
Δ5-desaturase
20:4 n-6/20:3 n-6 34.0 ± 10.1 31.8 ± 3.8 34.1 ± 6.3
Results are mean± SD; n= 8. Unpaired t-test. Signiﬁcance was set at p b 0.05.* vs control
and § vs HF.
Major fatty acids are represented and results are expressed as percentage of fatty acids in
total PL.
SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated
fatty acids.
£ SFA/MUFA: SFA = %C16:0 + %C18:0 and MUFA = %C16:1 + %C18:1.
# PUFA/SFA: SFA = %C16:0 + %C18:0 and PUFA = %all PUFA.
& n-3/PUFA: total (n-3) / all PUFA.
$ UI: unsaturation index = (% monoenoic*1) + (% dienoic*2) + (% trienoic*3) +
(% tetraenoic*4) + (% pentaenoic*5) + (% hexaenoic*6).
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increased with HF + MitoQ diet compared to HF diet (Fig. 1). Interest-
ingly, the CL content in liver phospholipids was positively correlated
with CDS1 mRNA expression (rh0 = 0.527, p = 0.0184) and highly
correlated with CLS mRNA expression (rh0 = 0.715, p = 0.0032).
The liver mRNA expression of other genes involved in CL biosynthesisFig. 1. Relative mRNA expression of genes involved in CL synthesis and remodeling. Results are
CDS1: CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 1; CDS2: CDP-diacylg
phate synthase 1; CLS: cardiolipin synthase; LCLAT1: lysocardiolipin acyltransferase 1; TAZ: ta(CDS2, PGS1) and CL remodeling (LCLAT1 and TAZ) remained un-
changed (Fig. 1).
3.8. Enzymatic activities of mitochondrial respiratory chain complexes and
correlations with CL content and fatty acid composition
The enzymatic activities of liver mitochondrial citrate synthase,
complex I, complex II and complex IV remained unchanged in the
three experimental groups. However, the enzymatic activities of
complex II + III and of ATP synthase were signiﬁcantly increased with
HF + MitoQ diet compared to HF diet and to control diet, respectively
(Table 7).
Moreover, the enzymatic activities of complex II and ATP synthase
were positively correlated with the CL content of liver phospholipids
(Fig. 2A, B), while the activities of complexes I, II + III and IV were not
correlated (not shown). The enzymatic activity of complex IV was
positively correlated with total PUFA (Fig. 2C) and with n-6 PUFA
content (not shown, rh0= 0.406; p= 0.0945) and negatively correlat-
ed with SFA content of mitochondrial phospholipids (Fig. 2D).
3.9. Correlation of mitochondrial membrane ﬂuidity, membrane potential,
ROS production and respiration with CL content and fatty acid composition
We recently published that liver mitochondrial respiration and ROS
production in vitro were unchanged by feeding the regimes used here,
but that the high fat diet increased mitochondrial membrane ﬂuidity
and potential [11]. To extend these results, we have reported here
positive correlations between liver mitochondrial CL content and
between mitochondrial membrane ﬂuidity, membrane potential and
respiration (Fig. 3A, B, C), and a negative correlation between liver
mitochondrial CL content and ROS production (Fig. 3D). Interestingly,
mitochondrial membrane potential and ﬂuidity were positively corre-
lated to the linoleic acid content of mitochondrial phospholipids
(rh0 = 0.538, p = 0.0098 and rh0 = 0.603, p = 0.0047 respectively)
(not shown), which is potentially interesting knowing that linoleic
acid is the major fatty acid of liver mitochondrial CL.
4. Discussion
We have previously observed that a high-fat diet in rats induced
major features of the metabolic syndrome, and that MitoQ intake
ameliorated the associated weight gain and glucose intolerance [11].
We speculated that the protective effect of MitoQmight be due tomod-
ulation of both redox signaling process and lipid metabolism. It is likely
that the presence of MitoQ adsorbed to the matrix surface of the mito-
chondrial inner membrane might modulate cellular and mitochondrial
membrane phospholipids, in particular CL, and their fatty acid composi-
tion, and that this in turn may contribute to the modulation of overallmean + SD; n = 8. Unpaired t-test. Signiﬁcance was set at p b 0.05.* vs control; § vs HF.
lycerol synthase (phosphatidate cytidylyltransferase) 2; PGS1: phosphatidyl glycerophos-
fazzin.
Table 7
Mitochondrial respiratory chain activities (IU/g mitochondrial protein).
Control diet HF diet HF + MitoQ diet
Citrate synthase 253 ± 20 257 ± 14 272 ± 21
Complex I 118 ± 20 119 ± 15 125 ± 22
Complex II 411 ± 70 415 ± 51 445 ± 34
Complex II + III 238 ± 52 206 ± 12 240 ± 37§
Complex IV (COX) 2184 ± 407 2318 ± 380 2359 ± 469
ATP synthase 942 ± 149 1070 ± 135 1143 ± 139*
Results are mean± SD; n= 8. Unpaired t-test. Signiﬁcance was set at p b 0.05.* vs control
and § vs HF.
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interaction/impact of the mitochondrial-targeting antioxidant, MitoQ,
with these membrane lipid parameters.
Our results show that MitoQ intake was accompanied by slight
but signiﬁcant decrease in food and energy intakes (about−10%) com-
pared to the HF group. The food consumption was rather stable during
the whole experimental period and thus the cause of this food intake
decrease did not seem due to food aversion. Indeed, previous animal
MitoQ supplementation studies did not show any signiﬁcant decrease
in food intake although MitoQ was administered for longer periods
and at higher dosages in mice or rats fed chow/control diets [20–22].
While the positive effects observed in the MitoQ administered rats
may be due in part to its effect on food intake, these are likely to play
a minor role in the effects we see here. This is because the decrease
in food consumption we see in the MitoQ group (~10%) is less than
25%–30% decrease compared to ad libitum caloric/dietary intake,
which is known to decrease body weight and to have beneﬁcial effects
on some metabolic syndrome features and aging [23,24]. Therefore, itFig. 2. Spearman correlation between CL content in liver mitochondrial PL andmitochondrial AT
drial COX activity and PUFA (C) and SFA content in liver mitochondrial PL (D).is unlikely that the observed beneﬁcial effects ofMitoQ can be explained
by the relatively slight decrease in food or energy intake in this study,
although a modest contribution cannot be excluded. Thus, it is likely
that MitoQ impacts other important physiological mechanisms, in
particular through possibly direct effects on both lipid metabolism and
mitochondrial activity and consequent changes in ROS production as
discussed below.4.1. MitoQ had no effect on total liver fatty acid composition
In this study, the liver fatty acid composition in rats fed the HF diet
was signiﬁcantly altered. The HF diet intake decreased SFA and PUFA
percent and increased MUFA percent and MitoQ did not affect signiﬁ-
cantly these modiﬁcations. The decrease in SFA level with the HF diet
was surprising because the SFA percent was 2.5 fold higher in the
fatty acids present in the HF diet fed to the rats, compared to the control
diet. SFAs are the ﬁrst product of de novo lipogenesis and are known
to exert lipotoxic effects, in particular palmitic acid, by promoting liver
fat accumulation, redox imbalance and ROS formation [25]. It is possible
that an increase in β-oxidation represents an adaptive mechanism
to limit free fatty acid lipotoxicity with the HF diet [26] and may ex-
plain the lower liver SFA percent found in our experiment,. In accor-
dance with this hypothesis, we observed that Δ9-desaturase activity,
as measured by the 16:1n-7/16:0 ratio, was signiﬁcantly decreased
with the HF diet. The Δ9 desaturase or stearoyl-CoA desaturase
(SCD1) is the rate limiting enzyme catalyzing the synthesis of MUFA
from SFA [27]. Consistent with this hypothesis, SCD1 (stearoyl-CoA
desaturase-1) gene expression was strongly down-regulated in a
dietary model of liver steatosis, resulting in enhanced delivery of SFA
to mitochondria and fatty acid oxidation [10]. On the other hand, theP synthase activity (A) andmitochondrial complex II activity (B), and betweenmitochon-
Fig. 3. Spearman correlation between CL content in livermitochondrial PL andmitochondrialmembraneﬂuidity (A),mitochondrialmembrane potential (B),mitochondrial respiration (C)
and mitochondrial ROS production (D).
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toxic than SFA and induce signiﬁcant triglycerides formation,
preventing the accumulation of toxic lipid intermediates. Moreover, as
previously observed [28], we found that the HF diet decreased the
trans fatty acid content compared to the control diet, perhaps indicating
that endogenously formed trans lipids could be rapidly replaced by the
abundant natural fats in the diet. MitoQ, however, had no signiﬁcant
effect on either liver fatty acid percent or trans fatty acids percent in
the overall liver lipids.
4.2. MitoQ had slight effects on liver phospholipids classes and their fatty
acid composition
The distribution of phospholipid classes in liver homogenates from
the control rats was in agreement with those previously published
[29–31]. PC and PE are the two major phospholipid classes and repre-
sent more than 80% of the total liver phospholipids. CL, the speciﬁc
mitochondrial phospholipid, represented about 5–6% of total phospho-
lipids in the liver homogenate. TheHFdiet induced signiﬁcantmodiﬁca-
tions in liver phospholipid class distribution but MitoQ did not affect
this. With both high fat diets, the PC percent was decreased and the
PE percent was increased compared to the control diet with a decrease
in the PC/PE ratio. It is known that the PC/PE ratio is a key regulator of
membrane integrity/ﬂuidity [32] and a decrease in PC/PE ratio is impli-
cated in the development of liver steatosis [33]. The observed increase
in the liver CL content with the HF diet seems to represent a CL enrich-
ment of the mitochondrial membrane.
It is known that dietary re-modulation of membrane phospholipids
can inﬂuence lipid metabolism [34]. The HF diet increased SFA content
while remained without effect on MUFA and PUFA contents; this is
consistent with the assumption that SFA are less efﬁciently esteriﬁed
into triglycerides lipid droplets thanMUFA, and are instead preferential-
ly incorporated into phospholipids and toxic lipid intermediates. In liver
phospholipids, total trans fatty acids content was not modiﬁed with theHF diet compared to controls. MitoQ had only a few effects as it
decreased MUFA content in liver phospholipids and trans 18:2n-6 con-
tent, and also Δ9-desaturase activity compared to the HF diet alone.
These observed effects probably resulted from changes induced by
MitoQ speciﬁcally onmitochondrial phospholipids. In fact, MitoQ intake
led to major effects on liver mitochondrial phospholipid distribution
and their fatty acid content, as developed below.
4.3. MitoQ had major effects on liver mitochondrial phospholipid
distribution and fatty acid composition
Interestingly, the PC/PE ratio in mitochondrial phospholipids was
decreasedwith the HF diet while CL content was signiﬁcantly increased
compared to the control diet. These results are in agreement with what
we, and others, have already observed in rats fed various HF diets [18,
35]. Phospholipids can serve as determinant of membrane lipid ﬂuidity
as either “ﬂuidizers” (as PC) or “rigidiﬁers” (as PE) [36] and the increase
in CL content with the HF diet probably contributes to preserving the
bioenergetic function of the mitochondria and compensates for the
altered PC/PE ratio that affects membrane properties. In line with this,
it was suggested that the liver can adapt toHF diet feeding by increasing
the activity of the mitochondrial oxidative phosphorylation chain and
its uncoupling, to dissipate the excess fatty acids and to reduce the
production of ROS [26]. Moreover, it was also suggested in diabetic
rats that mitochondria have the capacity to enhance the synthesis of
CL or adjust phospholipid metabolism, in order to decrease susceptibil-
ity to induction of the mitochondrial permeability transition [37]. We
have shown that the increased CL content in mitochondria from rats
fed the HF diet results, at least partly, from an increased synthesis of
CL as gene expression of two enzymes involved in CL synthesis (the
CDS1 that is involved in the ﬁrst step of CL synthesis and the CLS
which leads to formation of nascent CL) was signiﬁcantly increased
compared to controls. With MitoQ, the CL content was increased
compared to HF diet and CLS gene expression was also signiﬁcantly
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dria dynamics and bioenergetics that has not been reported before,
although we did not ﬁnd signiﬁcant variations in the CL content in
HF+MitoQ diet vs HFdiet in thewhole liver lipid extract. This inconsis-
tencymay be due to the higher concentration of CL in themitochondrial
lipid extract that renders its measurement more reliable.
The mitochondrial CL content was positively correlated to in vitro
measures of mitochondrial membrane ﬂuidity and potential, as well as
to respiration, while it was negatively correlated to mitochondrial ROS
production. Moreover, ATP synthase activity was positively correlated
to the CL content, as we have previously observed [18]. Thus, the
increase of CL content with the HF diet may preserve mitochondrial
bioenergetic function and MitoQ may help to reinforce the resistance
of mitochondria to metabolic stress. Our results are in agreement with
previous observations that CL has an inﬂuential effect on cellular respi-
ration [38]. The up-regulating effect of MitoQ on CLS gene expression
also reinforces the hypothesis that CLS has the unexpected role of
modulating the physiology of mitochondrial membranes, increasing
their resistance to metabolic stress [6] and enhancing mitochondrial
bioenergetic efﬁciency [39].
Besides phospholipid classes, fatty acid composition of biological
membranes also has a strong inﬂuence on their characteristics. In fact,
free fatty acids not only are essential fuels for the organism, but also
play also an essential role in the membrane composition and thus
modulate the structural properties and functions of many membrane
proteins. With the HF diet, SFA and PUFA contents were not modiﬁed
in mitochondrial membrane while MUFA content was decreased. If
high amounts of SFAs are incorporated into phospholipids inmitochon-
drial membrane bilayers, this can disturb organelle function as it signif-
icantly decreasesmembrane ﬂuidity; therefore the fact that SFA content
is not modiﬁed with the HF diet may be favorable to the mitochondrial
function. The PUFA/SFA ratio was decreased with the HF diet; however,
such a decrease may be advantageous for the mitochondrial membrane
as it makes the mitochondria less sensitive to oxidative stress and lipid
peroxidation [40]. In fact, the highly unsaturated nature of CL renders it
very susceptible to oxidation by mitochondrial ROS while CL peroxida-
tion may hamper mitochondrial efﬁciency and trigger mitochondrial
dysfunction and apoptosis. With MitoQ, 18:2n-6 (linoleic acid) content
was signiﬁcantly increased compared to control diet even if total PUFA
content was notmodiﬁed, while HF diet was low in linoleic acid. The in-
crease in linoleic acid content of mitochondrial phospholipids with
MitoQ probably results from linoleic acid enrichment of CL. In fact, the
two major phospholipids PC and PE of mitochondrial membrane are
composed principally of 20:4n-6 and SFAs while 18:2n-6 only accounts
for 10 and 5% in PC and PE, respectively [18]. Linoleic acid is the primary
fatty acid constituent of CL as it represents up to 50% to 70% of CL acyl
chains in the liver [18]. In order for CL to achieve its speciﬁc acyl compo-
sition, synthesized CL, or nascent/immature CL, undergoes acyl chain
remodeling that implicates principally tafazzin (TAZ) action [41]; CL re-
modeling increases the content of linoleic acid and leads to an increase
in the “good” or mature CL. However, the gene expression of two en-
zymes involved in remodeling of CL, TAZ and LCLAT1, was not modiﬁed
whatever the diet. It is possible that the remodeling of CL with MitoQ
does not occur at the transcriptional level. It was also demonstrated
that CLS has the ability to enhance tetra-18:2 molecular species content
of CL thereby helping in preventing pathological alterations to cardiac
mitochondrial lipidomic composition and bioenergetic function during
diabetes [39], and the same mechanisms could be involved with
MitoQ. Moreover, total trans fatty acids were signiﬁcantly decreased in
theMitoQ-fed rats, probably reﬂecting a positive local antioxidant effect
of MitoQ preventing lipid peroxidation as this effect was not observed
on total trans fatty acids or phospholipid trans fatty acid content. Partic-
ularly, CL, due to its high degree of unsaturation and its proximity to the
mitochondrial respiratory chain, is a likely target of ROS and is prone to
lipid peroxidation, and MitoQ may be effective in limiting its fatty acid
peroxidation. Moreover, MitoQ intake prevented the decrease in theUI induced by the HF diet. Together with the increase in linoleic acid
content and the decrease in trans fatty acid content, MitoQ may
preserve membrane physico-chemical properties and mitochondrial
function in the obesogenic diet-fed rats. The long chain PUFAs are
involved not only in membrane ﬂuidity but also in changing the bilayer
thickness with consequential differential exposure of membrane active
enzymes sites [42]. For example, the complex IV activity was positively
correlated to PUFA content, thus MitoQ may favorably inﬂuence its
functional properties. Δ9-desaturase activity was also decreased with
MitoQ compared to HF maybe reﬂecting amelioration of mitochondrial
function as this has been already suggested [10].
It is likely that these biochemical (fatty acids/CL amounts) and
physiological (mitochondrial membrane potential and ﬂuidity) modiﬁ-
cations by HF and MitoQ intake have impacted mitochondrial function
in particular ATP synthase activity. It is possible that the increase in
complex II + III activity, in the MitoQ group vs HF group, could be due
to preventing loss of the CoenzymeQ pool by MitoQ intake [43]. Such
a hypothesis deserves to be assessed in a separate study. The biochem-
ical/physiological modiﬁcations mentioned above increased the mito-
chondrial ATP synthase activity in the MitoQ group vs control group.
HF diet plus MitoQ intake increased ATP synthase activity signiﬁcantly.
Indeed, it has been reported that speciﬁc phospholipid classes and/or
their ratios, in particular CL, play a role in modulation of the activity of
this enzyme [44]. Moreover, it is known that ATP synthase activity is
modulated by membrane ﬂuidity [45]. Finally, it was suggested by
Degli Esposti et al. [46] that ubiquinone can interact directly with the
mitochondrial ATP synthase.
5. Conclusion
While accumulating evidence suggests amajor role formitochondri-
al dysfunction in the pathophysiology of fatty liver steatosis, it seems
thatmitochondria ﬁrst adapt to anHF diet by remodelingmitochondrial
membrane phospholipid content and fatty acid composition in order to
preserve their function. However, this compensatorymechanism seems
limited as ultimately decreased CL content and/or oxidative damage
have been observed in a range of pathological conditions associated
with mitochondrial dysfunction [47]. MitoQ may protect unsaturated
fatty acidmoieties from oxidative damage, thereby facilitating favorable
phospholipid remodeling of themitochondrialmembrane, with a possi-
ble positive impact on mitochondrial function. Indeed, the increase in
the liver mitochondrial CL content, that accompanied MitoQ intake,
was associated with an amelioration in mitochondrial respiration and
with a decrease in mitochondrial ROS production. This effect probably
results from the increased activity of some oxidative phosphorylation
complexes, in particular complex II + III and ATP synthase activity.
Moreover, MitoQ favorably increased linoleic acid content in mitochon-
drial membranes and decreased total content of trans fatty acids. These
changes are likely to underlie the positive effects on membrane ﬂuidity
and membrane potential, again preserving mitochondrial function.
Therefore, MitoQ might protect against, or at least slow down, changes
in CL proﬁles that may cause mitochondrial dysfunction and thereby
contribute to the development of the metabolic syndrome. Whether
MitoQ can restore CL proﬁles in other oxidative stress pathologies, and
thereby helps preserve bioenergetic efﬁciency and metabolic capacity,
remains to be explored.
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